Quick answer: Compounded semaglutide is semaglutide prepared by a state-licensed compounding pharmacy to fill one patient's prescription. It is not FDA-approved: the FDA does not review compounded drugs for safety, effectiveness or quality before they are sold, and compounded semaglutide is not a generic of Wegovy or Ozempic. It is still legal, but only in narrow cases. The FDA declared the semaglutide injection shortage resolved on February 21, 2025; the grace period ended on April 24, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities. Since then, a pharmacy generally can't make a copy of Wegovy or Ozempic unless the prescriber documents a significant difference for that patient. As of the FDA's April 1, 2026 update, semaglutide is on neither the drug shortage list nor the 503B bulks list. In our dataset (checked Oct 20, 2026), telehealth sellers listed compounded semaglutide at about $99 to $324 a month at the starting dose; Novo Nordisk's self-pay Wegovy pen is $349 a month and the Wegovy pill starts at $149 (NovoCare, checked Oct 20, 2026).
- Aug 7, 2026: FDA classified Class II recalls of 11 compounded semaglutide multi-dose vial products from Apollo Care for particulate matter, identified as nylon/polyamide and silk/protein-type material (D-0747-2026 to D-0757-2026). (FDA Enforcement Report)
- Jul 1, 2026: Medicare's GLP-1 Bridge opened, letting qualifying Part D enrollees get Wegovy (injection or tablet) for a $50 copay, alongside Zepbound and Foundayo, until the end of 2027; compounded drugs are not among the covered products. (Medicare.gov)
- Jun 26, 2026: The comment window on the bulks-list proposal was pushed out to July 30; as of our last check, the FDA has not issued a final determination. (Federal Register)
- May 31, 2026: Cut-off date for the FDA's latest count: 990 reports of adverse events linked to compounded semaglutide (published on its GLP-1 concerns page, updated Oct 1, 2026). (FDA)
- Apr 30, 2026: The agency proposed leaving semaglutide, along with tirzepatide and liraglutide, off the list of bulk substances outsourcing facilities may compound from; the notice ran in the Federal Register on May 1. (Federal Register)
- Apr 13, 2026: FDA classified a Class II recall of compounded semaglutide-glycine-B12 injections from Payless Compounders for lack of assurance of sterility (D-0471-2026). (FDA Enforcement Report)
- Apr 1, 2026: FDA restated the "essentially a copy" rule and its documented-difference exception, and confirmed semaglutide is on neither the shortage list nor the 503B bulks list. (FDA)
- Mar 17, 2026: Two New Life Pharma semaglutide vial recalls (D-0392-2026, D-0393-2026) were classified Class II because sterility could not be assured. On Mar 2 it had classified a recall of bulk semaglutide sold for compounding by Harbin Jixianglong Biotech, for manufacturing-practice deviations (D-0379-2026, D-0380-2026). (FDA Enforcement Report)
- Feb 24, 2026: Novo Nordisk announced it will cut the list price of Wegovy, Ozempic and Rybelsus to $675 a month from Jan 1, 2027; it says self-pay prices are not affected. (Novo Nordisk)
Last checked Oct 20, 2026. Sources: FDA (including its recall database), the Federal Register, Medicare.gov and Novo Nordisk.
Compounded semaglutide at a glance
The same active ingredient, made and regulated in different ways. Here is how a compounded preparation compares with Novo Nordisk's FDA-approved products.
| Compounded semaglutide | Wegovy / Ozempic (FDA-approved) | |
|---|---|---|
| FDA approval | Not FDA-approved. Not reviewed for safety, effectiveness or quality before sale | Approved: Wegovy for chronic weight management (and other uses), Ozempic for type 2 diabetes |
| Who makes it | A state-licensed 503A compounding pharmacy, for one patient's prescription | Novo Nordisk, under FDA manufacturing rules |
| Form | Usually a multi-dose vial you draw with a syringe | Pre-filled pen; Wegovy also comes as a daily pill |
| Dosing | You convert the prescribed mg into syringe units from the vial's mg/mL | Pen dials or fixed doses; no conversion |
| Clinical trials | None of its own | Large randomized trials of the branded products (the STEP program for Wegovy) |
| Insurance | Usually not covered | Sometimes covered, often with prior authorization |
| Monthly price | About $99 to $324 at the starting dose (15 telehealth sellers) | Wegovy pen $349 ($199 for a new patient's first 2 fills); Wegovy pill from $149 |
| Where it comes from | The compounding pharmacy, usually through a telehealth prescriber | Retail pharmacies or NovoCare Pharmacy |
Is compounded semaglutide still legal in 2026?
Yes, but narrowly. Until early 2025, semaglutide was in shortage, and the law gave compounders room to make copies. That room closed in 2025. Here is the timeline, from the FDA's own statements.
| Date | What happened | Source |
|---|---|---|
| Until Feb 2025 | Semaglutide injection products were on the FDA drug shortage list. During a shortage, the law gives compounders more room to make copies of the approved drug. | FDA statement |
| Feb 21, 2025 | The FDA determined the semaglutide injection shortage was resolved. It gave state-licensed (503A) pharmacies until April 22, 2025 and outsourcing facilities (503B) until May 22, 2025 to wind down, or until a court ruled in a pending lawsuit, whichever was later. | FDA, Feb 21 and Mar 10, 2025 entries |
| Apr 24, 2025 | A federal court in Texas denied a preliminary injunction in Outsourcing Facilities Association v. FDA. The FDA then said the 503A grace period had ended. | FDA, Apr 28, 2025 entry |
| May 22, 2025 | The 503B grace period ended for outsourcing facilities. | FDA, Apr 28, 2025 entry |
| Apr 1, 2026 | The FDA restated the rules: a 503A pharmacy may not make a product that is "essentially a copy" of an approved drug unless the prescriber documents a significant difference for the patient. It also said semaglutide is on neither the drug shortage list nor the 503B bulks list. | FDA, Apr 1, 2026 entry |
| May 1, 2026 | The FDA proposed not to add semaglutide, tirzepatide or liraglutide to the 503B bulks list. The comment period was extended to July 30, 2026. We found no final decision in the Federal Register as of Oct 20, 2026. | Federal Register 2026-08552; extension 2026-12937 |
| May 31, 2026 | The FDA had received 990 adverse event reports associated with compounded semaglutide (figure on the FDA page current as of Oct 1, 2026). | FDA concerns page |
What is allowed now
- A state-licensed 503A pharmacy may compound semaglutide for an individual patient's prescription.
- If the product would be "essentially a copy" of Wegovy or Ozempic (the same active ingredient, in the same, similar or easily substitutable strength, by the same route), the prescriber must determine and document that a change produces a significant difference for that patient, for example a dose that isn't sold commercially.
- The FDA has said it does not intend to act against a 503A compounder over copies if it fills four or fewer prescriptions of that compounded product in a calendar month (FDA, Apr 1, 2026).
What is not allowed
- Routine copies of Wegovy or Ozempic without a documented, patient-specific difference.
- Outsourcing facilities (503B) compounding from bulk semaglutide: it is on neither the shortage list nor the 503B bulks list.
- Salt forms (semaglutide sodium or acetate), which the FDA says have no lawful basis in compounding that it knows of.
- Selling it without a prescription. Vials sold without one, including ones labelled "for research use only", are not legitimate compounded medicine.
Was compounded semaglutide banned?
No. "Banned" is the most common way this gets reported, and it is wrong. What ended in 2025 was the shortage exception that let pharmacies make copies at scale. Compounding for an individual patient with a documented clinical need is still lawful under section 503A. What is pending is narrower: the FDA's May 2026 proposal concerns only the 503B bulks list, and the FDA had not finalized it as of Oct 20, 2026.
What compounded semaglutide costs in 2026
| Option | Status | Price | Source |
|---|---|---|---|
| Compounded semaglutide (weekly injection) | Not FDA-approved | About $99 to $324/mo at the starting dose, all-in, depending on the seller and plan length; some prices rise with the dose | Our dataset of 15 telehealth sellers, checked Oct 20, 2026 |
| Wegovy pen | FDA-approved | $349/mo at 0.25 to 2.4 mg; $199 for each of a new patient's first 2 fills at 0.25 or 0.5 mg (through Dec 31, 2026); $399 for Wegovy HD 7.2 mg | NovoCare, checked Oct 20, 2026 |
| Wegovy pill (daily) | FDA-approved | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg and $299 at 25 mg | NovoCare, checked Oct 20, 2026 |
| Ozempic pen (type 2 diabetes) | FDA-approved | $349/mo at 0.25 to 1 mg, $499 at 2 mg; $199 for a new patient's first 2 fills | NovoCare price guide, checked Oct 20, 2026 |
Compounded prices are quoted per month, per plan or per vial, sometimes with a separate membership. Converted to one all-in monthly figure at the starting dose, the 15 telehealth sellers in our dataset ranged from about $99 to $324 (checked Oct 20, 2026). Novo Nordisk's own self-pay prices are in the table for comparison.
Compounded semaglutide is not FDA-approved and not interchangeable with Wegovy or Ozempic, so these are not like-for-like prices. Prices change often; confirm at checkout. For the seller-by-seller breakdown, see compounded semaglutide cost; for every semaglutide option ranked, including the brands, see semaglutide cost and price; and for every GLP-1 ranked by monthly price, our GLP-1 cost comparison.
What compounded semaglutide is, and what it isn't
Compounding is a pharmacy making a medicine for one patient's prescription, usually because no approved product fits that patient. Compounded semaglutide is that: a preparation of the drug in Wegovy and Ozempic, mixed by a compounding pharmacy and usually supplied as a multi-dose vial.
- It is not a generic. There is no FDA-approved generic semaglutide in the US. A generic has to show the FDA it matches the brand; a compounded drug never goes through that review.
- It is not FDA-approved. The FDA does not check compounded drugs for safety, effectiveness or quality before they are sold (FDA's concerns with unapproved GLP-1 drugs, current as of Oct 1, 2026).
- Salt forms are a different drug. The FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved products, and that it is "not aware of any lawful basis" for compounding with them (same FDA page). If a label or website lists a salt form, treat that as a warning sign.
- Added B12 doesn't change the rules. Some pharmacies add vitamin B12 (cyanocobalamin). The FDA says a semaglutide and B12 product can still count as a copy of an approved drug when both strengths are within 10% of the commercially available products (FDA, Apr 1, 2026).
503A vs 503B pharmacies, in plain English
Two kinds of facility can compound, and the rules for semaglutide now differ between them.
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| What it is | A state-licensed pharmacy that compounds for individual prescriptions | A facility registered with the FDA that can make larger batches |
| Main oversight | State boards of pharmacy | The FDA, including federal manufacturing standards (CGMP) |
| Can it make semaglutide now? | Yes, for an individual patient's prescription; a copy of an approved drug needs a documented, patient-specific significant difference | Not from bulk semaglutide: it is on neither the shortage list nor the 503B bulks list, and the FDA proposed in May 2026 to keep it off |
| How to check one | Look the pharmacy up on your state board of pharmacy's license search | Search the FDA's registered outsourcing facilities list |
Is compounded semaglutide safe? What the FDA has warned about
The FDA hasn't evaluated any compounded semaglutide for safety, effectiveness or quality, so there is no approval to point to. What the agency has published is a list of specific problems (FDA concerns page, current as of Oct 1, 2026, unless noted):
- Dosing errors. The FDA has received reports of adverse events, some requiring hospitalization, that may be tied to dosing errors with compounded injectable semaglutide: patients measuring the wrong dose, and in some cases clinicians miscalculating it (FDA dosing-error alert). Vials are labelled in mg/mL but syringes are marked in units; our semaglutide dose calculator and mg to units calculator show the conversion for a dose your prescriber has set.
- Multi-dose vials. Use a new sterile needle and syringe every time, and discard the vial 28 days after first use, even if medication remains.
- Warm shipments. The FDA has received complaints of compounded GLP-1s arriving warm or with too little ice, and advises not using an injectable that arrives that way.
- Salt forms and fakes. Salt forms are different active ingredients. The FDA also warns about counterfeit products and labels with spelling errors or wrong pharmacy addresses.
- Adverse event reports. As of May 31, 2026, the FDA had received 990 reports of adverse events associated with compounded semaglutide. The FDA notes that federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events, so the true number may be higher.
The molecule's known side effects still apply. Wegovy's and Ozempic's labels list nausea, vomiting, diarrhea and constipation as common, and carry a boxed warning about thyroid C-cell tumors. A compounded product has no FDA-approved label of its own, so ask the prescriber to go through the risks with you. Read our Important Safety Information.
Does compounded semaglutide work? What the evidence covers
The trials behind semaglutide's weight-loss results studied the FDA-approved products, not compounded ones. In STEP 1, adults taking Wegovy 2.4 mg weekly lost about 14.9% of body weight on average over 68 weeks, versus 2.4% on placebo (Wilding et al., NEJM 2021). That result belongs to Wegovy in that trial. No compounded semaglutide product has its own efficacy trial, so no one can say a compounded preparation will produce the same result, and a seller that quotes Wegovy's trial numbers for its compounded product is misusing them.
How to tell a legitimate source
The FDA lists warning signs for online sellers of GLP-1s (FDA concerns page). Walk away from a company that:
- claims the compounded drug is the same as an FDA-approved drug;
- offers deep discounts or prices that seem too good to be true;
- doesn't require a screening and a prescription from a licensed clinician;
- has no licensed clinician available to answer questions after delivery;
- ships products with misspelled labels, unusual packaging or a wrong pharmacy address.
Then check the positives: the prescriber is licensed in your state, the provider names the pharmacy that compounds your order, and that pharmacy shows up on your state board of pharmacy's license search (or, for a 503B facility, on the FDA registered outsourcing facilities list). The FDA's BeSafeRx page explains how to check an online pharmacy. Our checklist for vetting semaglutide providers goes through each step.
How to get compounded semaglutide, if a clinician decides it fits
- See a licensed prescriber. In person or through a telehealth provider. They review your health history and decide whether semaglutide is appropriate, and whether a compounded preparation is justified for you.
- Know the pharmacy. Ask which state-licensed pharmacy will compound it, and check its license before you pay.
- Check the vial and the dose. Confirm the drug name, concentration and beyond-use date on arrival, refrigerate it, and convert your prescribed dose to syringe units before the first injection.
Our guide to buying compounded semaglutide online covers the online route step by step. Nouri is a publisher; it doesn't prescribe or sell medication.
Compounded semaglutide vs Wegovy and Ozempic
Wegovy and Ozempic are Novo Nordisk's FDA-approved semaglutide products, made under federal manufacturing rules, studied in large trials and sold at fixed doses in pens (Wegovy also as a pill). Compounded semaglutide shares the active ingredient but has none of that review, and it is usually priced lower. Our full comparison, compounded semaglutide vs Wegovy, goes through cost, FDA status and safety side by side.
Will compounded semaglutide stay available?
Under current FDA policy, yes for 503A compounding for individual patients, within the copy rules above. Two things could change that picture:
- The 503B bulks decision. If the FDA finalizes its May 2026 proposal, outsourcing facilities stay unable to compound from bulk semaglutide. That would not, on its own, end 503A compounding.
- FDA policy updates. The FDA has revised its compounding statement several times since 2024 (most recently on April 1, 2026) and keeps its concerns page current; a change there can tighten or loosen what pharmacies may do.
We re-check these FDA pages and the Federal Register and update this guide when either changes. The same proposal covers tirzepatide; our guide to compounded tirzepatide tracks its timeline.
Frequently asked questions
Is compounded semaglutide FDA-approved?
No. The FDA does not review compounded drugs for safety, effectiveness or quality before they are sold, and compounded semaglutide is not a generic of Wegovy or Ozempic.
Is compounded semaglutide legal in 2026?
Yes, but narrowly: since the FDA declared the shortage resolved on February 21, 2025 and the grace periods ended in April and May 2025, a state-licensed 503A pharmacy may compound it for an individual prescription. It may not make a copy of Wegovy or Ozempic unless the prescriber documents a significant difference for that patient.
Did the FDA ban compounded semaglutide?
No. The FDA ended the shortage-era flexibility in 2025, which put routine copies of the approved drugs off-limits, but compounding for an individual patient with a documented clinical need is still allowed.
Is compounded semaglutide the same as Ozempic?
No. Ozempic is Novo Nordisk's FDA-approved semaglutide for type 2 diabetes; compounded semaglutide shares the active ingredient but is not FDA-approved, was not studied in Ozempic's trials and is not interchangeable with it.
Is compounded semaglutide the same as Wegovy?
No. Wegovy is FDA-approved for chronic weight management and was studied in the STEP trials; compounded semaglutide was not, and the FDA lists a seller's claim that a compounded drug is the same as an approved drug as a warning sign.
Is compounded semaglutide safe?
The FDA has not reviewed it for safety, effectiveness or quality, and it had received 990 adverse event reports tied to compounded semaglutide as of May 31, 2026, some linked to dosing errors. Much depends on the pharmacy and the prescriber, so check both and ask your clinician about the risks.
Can you still buy compounded semaglutide?
Yes, with a prescription from a licensed clinician, filled by a state-licensed pharmacy; telehealth sellers in our dataset listed it at about $99 to $324 a month at the starting dose (checked Oct 20, 2026). A seller that skips the prescription is a red flag.
What is in compounded semaglutide?
It should contain semaglutide itself: the FDA says salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients and knows of no lawful basis for compounding with them. Some pharmacies add vitamin B12, and the FDA says a semaglutide and B12 product can still count as a copy when both strengths are within 10% of commercial products.
Is compounded semaglutide a generic?
No. There is no FDA-approved generic semaglutide in the US; compounded semaglutide is a pharmacy-made preparation that is not FDA-approved.
Does insurance or an HSA cover compounded semaglutide?
Insurance plans usually do not cover compounded drugs. An FSA or HSA may reimburse a prescribed medication, depending on your plan administrator.
How long does compounded semaglutide last in the fridge?
Follow the storage directions and beyond-use date on your pharmacy's label, because they vary by preparation. Once you open a multi-dose vial, the FDA advises throwing it away 28 days after first use, even if medication remains.
What is semaglutide injection used for?
As FDA-approved products: Wegovy for chronic weight management, and to lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight; Ozempic for type 2 diabetes. Compounded semaglutide has no FDA-approved use of its own.
How is tirzepatide different from Ozempic?
Ozempic is semaglutide from Novo Nordisk, which acts on the GLP-1 receptor; tirzepatide (Eli Lilly's Mounjaro and Zepbound) acts on both the GIP and GLP-1 receptors. They are different molecules with different doses and labels; a compounded form of either has no FDA approval.
What's the least expensive way to get semaglutide?
Without insurance, the FDA-approved Wegovy pill is $149 a month at its starting dose through NovoCare (checked Oct 20, 2026), and the lowest compounded prices we've seen are about $99 a month, mostly on 12-month plans; compounded semaglutide is not FDA-approved. With commercial coverage, Novo's savings offers can bring Wegovy or Ozempic to as little as $25, and eligible Medicare Part D members pay $50 for Wegovy through the Medicare GLP-1 Bridge.
Can I use compounded semaglutide after 28 days?
Not from an opened multi-dose vial: the FDA advises discarding it 28 days after first use, even if some is left. An unopened vial follows the beyond-use date on the pharmacy label.
Sources and references
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (entries of Feb 21, 2025, Mar 10, 2025, Apr 28, 2025 and Apr 1, 2026; checked Oct 20, 2026)
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of Oct 1, 2026; checked Oct 20, 2026)
- FDA: alert on dosing errors associated with compounded injectable semaglutide
- Federal Register 2026-08552: List of bulk drug substances for which there is a clinical need under section 503B (May 1, 2026) and extension of comment period, 2026-12937 (June 26, 2026)
- FDA: Compounding and the FDA, questions and answers
- FDA: Registered outsourcing facilities
- FDA: BeSafeRx, your source for online pharmacy information
- NovoCare: Wegovy self-pay prices and Ozempic price guide (checked Oct 20, 2026)
- FDA Enforcement Report: recalls D-0379-2026, D-0380-2026, D-0392-2026, D-0393-2026, D-0471-2026 and D-0747-2026 to D-0757-2026 (checked Oct 20, 2026)
- Novo Nordisk: significant reduction in US list price for Wegovy, Ozempic and Rybelsus (Feb 24, 2026)
- Medicare GLP-1 Bridge eligibility and covered drugs (Medicare.gov), read Oct 20, 2026
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021 (trial of the branded drug, cited for context only)
Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Nouri is not affiliated with Novo Nordisk. Nouri is a publisher; it does not prescribe, compound or sell any medication. This guide is general information, not medical or legal advice: a licensed prescriber decides whether semaglutide, compounded or not, fits you. Compounded semaglutide is not FDA-approved and has not been evaluated by the FDA for safety, effectiveness or quality.
Disclosure: Nouri may earn a commission when you sign up with some of the providers we link to. It doesn't change what you pay or how we rank providers. Full disclosure.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Nouri is an independent publisher: it does not prescribe, review patient assessments, or sell medication. Talk to a licensed clinician before starting or changing any medication or treatment.
Compare licensed GLP-1 providers
Published cash prices side by side, with the month we checked them and a link to each provider's own site. Nouri doesn't prescribe or sell medication.